Nexien Biopharma Stock Performance
| NXEN Stock | USD 0.01 0.01 35.00% |
Nexien Biopharma holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.83, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nexien Biopharma will likely underperform. Use Nexien Biopharma semi variance, as well as the relationship between the daily balance of power and price action indicator , to analyze future returns on Nexien Biopharma.
Risk-Adjusted Performance
10 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Nexien Biopharma are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady technical and fundamental indicators, Nexien Biopharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 18 K | |
| Free Cash Flow | -75.1 K |
Nexien |
Nexien Biopharma Relative Risk vs. Return Landscape
If you would invest 1.90 in Nexien Biopharma on August 29, 2024 and sell it today you would lose (0.60) from holding Nexien Biopharma or give up 31.58% of portfolio value over 90 days. Nexien Biopharma is currently generating 4.5727% in daily expected returns and assumes 35.1769% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Nexien, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nexien Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nexien Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Nexien Biopharma, and traders can use it to determine the average amount a Nexien Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.13
| Best Portfolio | Best Equity | NXEN | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 35.18 actual daily | 96 96% of assets are less volatile |
Expected Return
| 4.57 actual daily | 91 91% of assets have lower returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Nexien Biopharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nexien Biopharma by adding it to a well-diversified portfolio.
Nexien Biopharma Fundamentals Growth
Nexien Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Nexien Biopharma, and Nexien Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nexien Pink Sheet performance.
| Return On Equity | -40.7 | |||
| Return On Asset | -5.99 | |||
| Current Valuation | 2.58 M | |||
| Shares Outstanding | 62.77 M | |||
| Price To Book | 205.41 X | |||
| EBITDA | (563.99 K) | |||
| Cash And Equivalents | 116.9 K | |||
| Total Debt | 221.73 K | |||
| Debt To Equity | 0.36 % | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (75.14 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 124.52 K | |||
About Nexien Biopharma Performance
By examining Nexien Biopharma's fundamental ratios, stakeholders can obtain critical insights into Nexien Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Nexien Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Nexien Biopharma performance evaluation
Checking the ongoing alerts about Nexien Biopharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Nexien Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nexien Biopharma is way too risky over 90 days horizon | |
| Nexien Biopharma has some characteristics of a very speculative penny stock | |
| Nexien Biopharma appears to be risky and price may revert if volatility continues | |
| Nexien Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Nexien Biopharma currently holds 221.73 K in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Nexien Biopharma has a current ratio of 0.5, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nexien Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nexien Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nexien Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nexien to invest in growth at high rates of return. When we think about Nexien Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (626.36 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nexien Biopharma currently holds about 116.9 K in cash with (75.14 K) of positive cash flow from operations. | |
| Roughly 54.0% of Nexien Biopharma outstanding shares are owned by corporate insiders |
- Analyzing Nexien Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nexien Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Nexien Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nexien Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nexien Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nexien Biopharma's pink sheet. These opinions can provide insight into Nexien Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.